Antibody Information
General Information of This Antibody
| Antibody ID | ANTI0AZABC |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | FS001-huVH3-huVL2 |
|||||
| Organization | FORESEEN TECHNOLOGY (BEIJING) CO., LTD. |
|||||
| Synonyms |
FS001-huVH3-huVL2
Click to Show/Hide
|
|||||
| Antigen Name | Glypican-3 (GPC3) |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
| Heavy Chain Sequence |
QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYEMHWVRQAPGQGLEWIGGIHPGSGGTAY
NOKFOGRVTLTADTSISTAYMELSRLRSDDTAVYYCTRYYSFAYWGOGTTVTVSSASTKG PSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLOSSGLYSL SSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFL FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRV VSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQ VSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNV FSCSVMHEALHNHYTQKSLSLSPGK Click to Show/Hide
|
|||||
| Heavy Chain Varible Domain |
QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYEMHWVRQAPGQGLEWIGGIHPGSGGTAY
NOKFOGRVTLTADTSISTAYMELSRLRSDDTAVYYCTRYYSFAYWGOGTTVTVSS Click to Show/Hide
|
|||||
| Heavy Chain Constant Domain 1 |
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLOSS
GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW QQGNVFSCSVMHEALHNHYTQKSLSLSPGK Click to Show/Hide
|
|||||
| Heavy Chain CDR 1 |
DYEMH
Click to Show/Hide
|
|||||
| Heavy Chain CDR 2 |
GIHPGSGGTAYNOKFOG
Click to Show/Hide
|
|||||
| Heavy Chain CDR 3 |
YYSFAYWGOG
Click to Show/Hide
|
|||||
| Light Chain Sequence |
DVVMTQSPLSLPVTLGQPASISCRSSOSLVHSNGNTYLQWFQQRPGQSPRLLIYKVSNRF
SGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSOSIHVPYTFGGGTKLEIKRTVAAPSV FIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSL SSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Click to Show/Hide
|
|||||
| Light Chain Varible Domain |
DVVMTQSPLSLPVTLGQPASISCRSSOSLVHSNGNTYLQWFQQRPGQSPRLLIYKVSNRF
SGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSIHVPYTFGGGTKLEIK Click to Show/Hide
|
|||||
| Light Chain Constant Domain |
RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD
SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Click to Show/Hide
|
|||||
| Light Chain CDR 1 |
RSSQSLVHSNGNTYLQ
Click to Show/Hide
|
|||||
| Light Chain CDR 2 |
KVSNRFS
Click to Show/Hide
|
|||||
| Light Chain CDR 3 |
CSQSIHVPY
Click to Show/Hide
|
|||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
FS001-VH3-VL2-Vc-MMAE [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.16 nM
|
Positive GPC3 expression (GPC3+++/++) | ||
| Method Description |
HuH7 2500cell/well were plated at set initial densities in 96 well flat bottom plates in the appropriate growth media. 24 hours later, dosing solutions were added with a 3-fold dilution across 11 points, for the various ADCs. Cell proliferation was measured after 5 days exposure, 100ul Cell titer glo 2.0 to test IC50.
|
||||
| In Vitro Model | Adult hepatocellular carcinoma | HuH7 cells | CVCL_0336 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.61 nM
|
Positive GPC3 expression (GPC3+++/++) | ||
| Method Description |
HepG2 2500cell/well were plated at set initial densities in 96 well flat bottom plates in the appropriate growth media. 24 hours later, dosing solutions were added with a 3-fold dilution across 11 points, for the various ADCs. Cell proliferation was measured after 5 days exposure, 100ul Cell titer glo 2.0 to test IC50.
|
||||
| In Vitro Model | Hepatoblastoma | HepG2 cells | CVCL_0027 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | > 207 nM | Negative GPC3expression (GPC3-) | ||
| Method Description |
CHO 2500cell/well were plated at set initial densities in 96 well flat bottom plates in the appropriate growth media. 24 hours later, dosing solutions were added with a 3-fold dilution across 11 points, for the various ADCs. Cell proliferation was measured after 5 days exposure, 100ul Cell titer glo 2.0 to test IC50.
|
||||
| In Vitro Model | Normal | CHO cells | CVCL_0213 | ||
References